

## **AstraZeneca – Call For Grant Applications (CGA COPD 1801)**

<b>Submission / Review Timeline:</b>	Accepting applications until 5 PM EST on March 30, 2019; internal review will be ongoing during this time period
<b>Primary Area of Focus</b>	Respiratory
<b>Therapeutic Area</b>	COPD
<b>Educational Design</b>	Accredited medical education programs designed to address independently identified gaps and attitudinal barriers to improve clinical performance of healthcare providers and person care
<b>Educational Audience:</b>	Pulmonologists and primary care
<b>Program Cost:</b>	≤ \$325,000.00
<b>CGA Code</b>	CGA COPD 1801
<b>Website URL</b>	<a href="https://www.astrazenecagrants.com/us-grants.html">https://www.astrazenecagrants.com/us-grants.html</a>

### **Background on COPD**

Chronic Obstructive Pulmonary Disease (COPD) is an important public health issue, as evidenced by the prevalence in the US as well as the world, the burden to the patient and caregiver, the costs to the healthcare system, the number of organizations dedicated to supporting the members of the COPD community, including patients, caregivers, health care providers, and nonprofit organizations. The challenges regarding the continuum of care of patients with COPD are vast: heterogeneity of the disease; difficulty with early stage diagnosis; predictors of exacerbations not fully elucidated; patient needs and how related to the adherence to medications/devices; comorbidities that may aggravate COPD (eg, pneumonia); large number of on-going clinical trials and real world evidence studies; annual updates to guidelines and challenges for timely translation into clinical practice; etc.

AstraZeneca is interested in supporting timely and relevant, high quality, practical independent medical education with the highest likelihood of addressing independently identified gaps and attitudinal barriers to improve clinical performance of those partnering with patients in their management of COPD.

Topics may include:

- Guideline concordant algorithms for initiation and follow-up management of pharmacological treatments
- Definitions and implications of exacerbations in patients with COPD (mild, moderate, severe)
- The relationship of comorbidities and treatment choices in COPD
- Patient preference for attributes of inhalers

### **References**

1. Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease (COPD). Assessed November 11, 2018 at: <https://www.cdc.gov/copd/resources.html>.
2. 2019 GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD. Accessed November 11, 2018 at: <https://goldcopd.org/gold-reports/>.
3. Qureshi H, Sharafkhaneh A and Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. *Ther Adv Chronic Dis*. 2014;5:212-227.
4. U.S. National Library of Medicine. ClinicalTrials.gov. Assessed November 11, 2018 at: <https://clinicaltrials.gov/ct2/results?cond=COPD&term=&cntry=&state=&city=&dist=>.
5. Houben-Wilke S, Augustin IM, Vercoulen JH, et al. COPD stands for complex obstructive pulmonary disease. *Eur Respir Rev* 2018; 27: 180027 [https://doi.org/10.1183/16000617.0027-2018].

### **Program Requirements:**

The Program must be accredited and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and the ACCME Standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.